-
公开(公告)号:US20100279970A1
公开(公告)日:2010-11-04
申请号:US12771289
申请日:2010-04-30
IPC分类号: A61K31/7076 , A61P27/06 , A61P27/02
CPC分类号: C07H19/16 , A61K31/7076
摘要: Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for reducing intraocular pressure comprising administering an effective amount of compounds of Formula I to a subject in need thereof.
摘要翻译: 本文提供式I化合物,包含有效量的式I化合物的组合物和降低眼内压的方法,其包括向有需要的受试者施用有效量的式I化合物。
-
公开(公告)号:US20110172177A1
公开(公告)日:2011-07-14
申请号:US13004380
申请日:2011-01-11
IPC分类号: A61K31/7076 , A61K31/216 , A61K31/19 , A61K31/165 , A61P27/02
CPC分类号: A61K31/7076 , A61K9/0048 , A61K31/165 , A61K31/19 , A61K31/216 , A61K31/5575 , A61K45/06 , C07H19/16 , A61K2300/00
摘要: The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The invention is particularly directed to a combination of latanoprost marketed under the brand Xalatan™ and Compound A.
摘要翻译: 本发明涉及包含前列腺素类似物和腺苷受体A1激动剂的组合或试剂盒,以及使用这种组合或试剂盒降低受试者的眼内压(IOP)的方法。 本发明特别涉及以品牌Xalatan TM和化合物A销售的拉坦前列素的组合。
-